Solar Foods protein from carbon dioxide gets authorisation
Finnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Bone Therapeutics merges with Medsenic and changes name
/in News/by Thomas GabrielczykBone Therapeutics has merged with French inflammatory/autoimmune company Medsenic in a 40m deal and changed its name into BioSenic.
Resolve Biosciences secures US$71m in funding
/in News/by Thomas GabrielczykMolecular cartography company Resolve Biosciences has raised $71m in series B funding co-led by Patient Square Capital, EDBI, Alafi Capital and NRW.BANK as well as other existing investors.
Enhanc3D Genomics raises £10m in Series A financing
/in News/by Thomas GabrielczykCambridge-based Enhanc3D Genomics Ltd has raised £10m in Series A financing led by BGF and Parkwalk Advisors.
Univercells SA raises 44m in first close of its Series D
/in News/by Thomas GabrielczykBelgian CDMO Univercells SA has raised 44m through the first close of its Series D financing round led by Belgian and international investors. I
Adrenomed set to start pivotal trial in sepsis
/in News/by Thomas GabrielczykGerman Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study.
Mablink raises $31m in Series A financing
/in News/by Thomas GabrielczykMablink Bioscience has baged 31m in a Series A round led by Sofinnova Partners and Mérieux Equity Partners to speed up its pipeline of ADCs.
Experts showcase next-gen biotech solutions to climate crisis
/in News/by Thomas GabrielczykIndustry experts have presented the latest biotech solutions for tackling climate change at the first INDUSTRIA BIOTEC conference, Europe’s new forum for the industrial biotech sector.
Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01
/in News/by Thomas GabrielczykPrecision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia.
Clinical Microbiomics A/S bags 10m financing
/in News/by Thomas GabrielczykDanish microbiome specialist Clinical Microbiomics A/S has completed a 10m growth financing led by Seventure Partners.